256 related articles for article (PubMed ID: 32653588)
1. The voltage-gated potassium channel K
Tajti G; Wai DCC; Panyi G; Norton RS
Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
[TBL] [Abstract][Full Text] [Related]
2. Treating autoimmune disorders with venom-derived peptides.
Shen B; Cao Z; Li W; Sabatier JM; Wu Y
Expert Opin Biol Ther; 2017 Sep; 17(9):1065-1075. PubMed ID: 28695745
[TBL] [Abstract][Full Text] [Related]
3. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
4. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
5. Voltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy.
Cheng S; Jiang D; Lan X; Liu K; Fan C
Biomed Pharmacother; 2024 Jun; 175():116651. PubMed ID: 38692062
[TBL] [Abstract][Full Text] [Related]
6. Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries.
Zhang H; Du M; Xie J; Liu X; Sun J; Wang W; Xin X; Possani LD; Yea K; Lerner RA
Angew Chem Int Ed Engl; 2016 Aug; 55(32):9306-10. PubMed ID: 27197631
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
8. Conformational exchange in the potassium channel blocker ShK.
Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
[TBL] [Abstract][Full Text] [Related]
9. Venom-derived peptide inhibitors of voltage-gated potassium channels.
Norton RS; Chandy KG
Neuropharmacology; 2017 Dec; 127():124-138. PubMed ID: 28689025
[TBL] [Abstract][Full Text] [Related]
10. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
[TBL] [Abstract][Full Text] [Related]
11. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the Inhibitory Peptides ShK and HmK with the Voltage-Gated Potassium Channel K
Sanches K; Prypoten V; Chandy KG; Chalmers DK; Norton RS
J Chem Inf Model; 2023 May; 63(10):3043-3053. PubMed ID: 37143234
[TBL] [Abstract][Full Text] [Related]
13. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
14. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
16. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
Pérez-Verdaguer M; Capera J; Serrano-Novillo C; Estadella I; Sastre D; Felipe A
Expert Opin Ther Targets; 2016; 20(5):577-91. PubMed ID: 26634786
[TBL] [Abstract][Full Text] [Related]
17. Novel Kv1.3 blockers for immunosuppression: WO2012155199.
Nguyen W
Expert Opin Ther Pat; 2013 Nov; 23(11):1511-6. PubMed ID: 23968576
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
Edwards W; Fung-Leung WP; Huang C; Chi E; Wu N; Liu Y; Maher MP; Bonesteel R; Connor J; Fellows R; Garcia E; Lee J; Lu L; Ngo K; Scott B; Zhou H; Swanson RV; Wickenden AD
J Biol Chem; 2014 Aug; 289(33):22704-22714. PubMed ID: 24939846
[TBL] [Abstract][Full Text] [Related]
19. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
Wang J; Xiang M
Pharmacotherapy; 2013 May; 33(5):515-28. PubMed ID: 23649812
[TBL] [Abstract][Full Text] [Related]
20. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins.
Prentis PJ; Pavasovic A; Norton RS
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
